Serum and cerebrospinal fluid prolactin levels in male and female patients with clinically-isolated syndrome or relapsing-remitting multiple sclerosis

Journal of Neuroendocrinology

Volumn 22, Issue 6, 2010, Pages 503-508

  Markianos, M ^a   Koutsis, G ^a   Evangelopoulos, M E ^a   Mandellos, D ^a   Sfagos, C ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Clinically isolated syndrome; CSF; Multiple sclerosis; Prolactin; Serum

Indexed keywords

PROLACTIN;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; BRAIN INJURY; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROPROTECTION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RELAPSE; REMYELINIZATION; SEX DIFFERENCE; ADOLESCENT; BLOOD; CASE CONTROL STUDY; CEREBROSPINAL FLUID; DEMYELINATING DISEASE; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; DEMYELINATING DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROLACTIN; YOUNG ADULT;

EID: 77954092215     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2010.01972.x     Document Type: Article

References (40)

1. Grattan DR, Kokay IC. Prolactin: a pleiotropic neuroendocrine hormone. J Neuroendocrinol 2008, 20:752-763.
2. Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev 1996, 17:639-669.
3. Orbach H, Shoenfeld Y. Hyperprolactinemia and autoimmune diseases. Autoimmun Rev 2007, 6:537-542.
4. De Bellis A, Bizzarro A, Pivonello R, Lombardi G, Bellastella A. Prolactin and autoimmunity. Pituitary 2005, 8:25-35.
5. Buskila D, Lorber M, Neumann L, Flusser D, Shoenfeld Y. No correlation between prolactin levels and clinical activity in patients with systemic lupus erythematosus. J Rheumatol 1996, 23:629-632.
6. Vera-Lastra O, Mendez C, Jara LJ, Cisneros M, Medina G, Ariza R, Espinoza LR. Correlation of prolactin serum concentrations with clinical activity and remission in patients with systemic lupus erythematosus. Effect of conventional treatment. J Rheumatol 2003, 30:2140-2146.
7. Grinsted L, Heltberg A, Hagen C, Djursing H. Serum sex hormone and gonadotropin concentrations in premenopausal women with multiple sclerosis. J Intern Med 1989, 226:241-244.
8. Kira J, Harada M, Yamaguchi Y, Shida N, Goto I. Hyperprolactinemia in multiple sclerosis. J Neurol Sci 1991, 102:61-66.
9. Zych-Twardowska E, Wajgt A. Serum prolactin and sex hormone concentrations in patients with multiple sclerosis. Med Sci Monit 1999, 5:216-220.
10. Yamasaki K, Horiuchi I, Minohara M, Osoegawa M, Kawano Y, Ohyagi Y, Yamada T, Kira J. Hyperprolactinemia in optico-spinal multiple sclerosis. Intern Med 2000, 39:296-309.
11. Reder AT, Lowy MT. Serum prolactin levels in active multiple sclerosis and during cyclosporin treatment. J Neurol Sci 1993, 117:192-196.
12. Harirchian MH, Sahraian MA, Shirani A. Serum prolactin level in patients with multiple sclerosis: a case control study. Med Sci Monit 2006, 12:CR177-180.
13. Wei T, Lightman SL. The neuroendocrine axis in patients with multiple sclerosis. Brain 1997, 120:1067-1076.
14. Heesen C, Gold SM, Bruhn M, Mönch A, Schulz KH. Prolactin stimulation in multiple sclerosis - an indicator of disease subtypes and activity? Endocr Res 2002, 28:9-18.
15. Markianos M, Sfagos C. Plasma testosterone, prolactin, luteinizing hormone, and disease activity in male multiple sclerosis patients. Neuro Endocrinol Lett 1989, 11:53-58.
16. Walsh RJ, Slaby FJ, Posner BI. A receptor-mediated mechanism for the transport of prolactin from blood to cerebrospinal fluid. Endocrinology 1987, 120:1846-50.
17. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol 2005, 58:840-846.
18. Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, Galetta SL, Hutchinson M, Johnson RT, Kappos L, Kira J, Lublin FD, McFarland HF, Montalban X, Panitch H, Richert JR, Reingold SC, Polman CH. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008, 14:1157-1174.
19. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
20. Halbreich U, Kinon BJ, Gilmore JA, Kahn LS. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 2003, 28(suppl.1):53-67.
21. Riskind PN, Massacesi L, Doolittle TH, Hauser SL. The role of prolactin in autoimmune demyelination: suppression of experimental allergic encephalomyelitis by bromocriptine. Ann Neurol 1991, 29:542-547.
22. Bissay V, De Klippel N, Herroelen L, Schmedding E, Buisseret T, Ebinger G, De Keyser J. Bromocriptine therapy in multiple sclerosis: an open label pilot study. Clin Neuropharmacol 1994, 17:473-476.
23. Jara LJ, Irigoyen L, Ortiz MJ, Zazueta B, Bravo G, Espinoza LR. Prolactin and interleukin-6 in neuropsychiatric lupus erythematosus. Clin Rheumatol 1998, 17:110-4.
24. Chikanza IC. Prolactin and neuroimmunomodulation: in vitro and in vivo observations. Ann NY Acad Sci 1999, 876:119-130.
25. Frisullo G, Nociti V, Iorio R, Patanella AK, Marti A, Caggiula M, Mirabella M, Tonali PA, Batocchi AP. IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis. Cytokine 2008, 44:22-25.
26. Nguyen LT, Ramanathan M, Weinstock-Guttman B, Baier M, Brownscheidle C, Jacobs LD. Sex differences in in vitro pro-inflammatory cytokine production from peripheral blood of multiple sclerosis patients. J Neurol Sci 2003, 209:93-99.
27. Moldovan IR, Cotleur AC, Zamor N, Butler RS, Pelfrey CM. Multiple sclerosis patients show sexual dimorphism in cytokine responses to myelin antigens. J Neuroimmunol 2008, 193:161-169.
28. Tomassini V, Onesti E, Mainero C, Giugni E, Paolillo A, Salvetti M, Nicoletti F, Pozzilli C. Sex hormones modulate brain damage in multiple sclerosis: MRI evidence. J Neurol Neurosurg Psychiatry 2005, 76:272-275.
29. Gregg C, Shikar V, Larsen P, Mak G, Chojnacki A, Yong VW, Weiss S. White matter plasticity and enhanced remyelination in the maternal CNS. J Neurosci 2007, 27:1812-1823.
30. Möderscheim TA, Gorba T, Pathipati P, Kokay IC, Grattan DR, Williams CE. Prolactin is involved in glial responses following a focal injury to the juvenile rat brain. Neuroscience 2007, 145:963-973.
31. Pozzilli C, Tomassini V, Marinelli F, Paolillo A, Gasperini C, Bastianello S. 'Gender gap' in multiple sclerosis: magnetic resonance imaging evidence. Eur J Neurol 2003, 10:95-97.
32. Stevens JR. Schizophrenia and multiple sclerosis. Schizophr Bull 1988, 14:231-241.
33. Surridge D. An investigation into some psychiatric aspects of multiple sclerosis. Br J Psychiatry 1969, 115:749-764.
34. Joffe RT, Lippert GP, Gray TA, Sawa G, Horvath Z. Mood disorder and multiple sclerosis. Arch Neurol 1987, 44:376-378.
35. Diaz-Olavarrieta C, Cummings JL, Velazquez J, Garcia de la Cadena C. Neuropsychiatric manifestations of multiple sclerosis. J Neuropsychiatry Clin Neurosci 1999, 11:51-57.
36. Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and undertreated. Mult Scler 2009, 15:385-392.
37. Feinstein A, du Boulay G, Ron MA. Psychotic illness in multiple sclerosis. A clinical and magnetic resonance imaging study. Br J Psychiatry 1992, 161:680-685.
38. Stommel E, Graber D, Montanye J, Cohen J, Harris B. Does treating schizophrenia reduce the chances of developing amyotrophic lateral sclerosis? Med Hypotheses 2007, 69:1021-1028.
39. Nielsen NM, Rostgaard K, Rasmussen S, Koch-Henriksen N, Storm HH, Melbye M, Hjalgrim H. Cancer risk among patients with multiple sclerosis: a population-based register study. Int J Cancer 2006, 15:979-984.
40. La Torre D, Falorni A. Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag 2007, 3:929-951.